The Baxter International 2Q17 Story: Key Highlights
Baxter International’s EPS
On July 26, 2017, Baxter International (BAX) released its 2Q17 results, reporting adjusted diluted EPS (earnings per share) of $0.63, compared with $0.46 in 2Q16. This represents a rise of ~37% on a YoY (year-over-year) basis.
Interested in BAX? Don't miss the next report.
Receive e-mail alerts for new research on BAX
Baxter’s 2Q17 EPS exceeded the Wall Street analysts’ estimate of $0.57, coming in well ahead of its own guidance range of $0.55–$0.57. Continued operational strength and business transformation initiatives led to this rise in earnings.
BAX registered revenues of ~$2.6 billion in 2Q17, which was 0.77% higher YoY. Marginal sales growth was mainly driven by strength across the company’s US businesses, and robust international operational growth also drove sales. In the US, the systems nutrition and anesthesia portfolios both registered strong growth, while international growth across BAX’s peritoneal dialysis and acute renal therapies portfolio was a major driver for sales in 2Q17.
Baxter’s Hospital Products sales witnessed 4% operational sales growth, while its renal business registered 3% growth in operational sales.
By comparison, peers ResMed (RMD), Becton, Dickinson, and Company (BDX), and Abbott Laboratories (ABT) registered revenues of ~$0.56 billion, ~$3.03 billion, and ~$6.6 billion, respectively, in their most recently reported quarters.
For diversified exposure to Baxter International, investors can consider the Vanguard S&P 500 ETF (VOO), which has ~0.11% of its total holdings in BAX.